Dr. Yan Peng completed her Pediatric Residency/Chief Resident at Beijing Medical University Hospitals and practiced there as a Pediatric Nephrologist for two years. After a combined six years of basic research on kidney disease at Mayo Clinic and Foundation and UT-Southwestern Medical Center (UTSW), she went to University of Pittsburgh Medical Center (UPMC) for Pathology Residency. Upon the completion, she took two fellowship trainings in Breast and Gynecologic Pathology and Cytopathology at UPMC and Harvard Medical School, respectively.
She has been a Breast and Gynecologic Surgical Pathologist and Cytopathologist at the UTSW. She is the Pathology Liaison at Cancer Committee of UTSW Simmons Cancer Center and University Hospital. She served as Medical Directors of Diagnostic Immunohistochemistry Laboratory and Tumor Biomarker Image Analysis Laboratory for about 10 years. As co-investigator, she has participated in more than 30 National Cancer Institute (NCI) Breast and Gynecologic cancer clinical trials. She has served as an investigator for NCI Cancer Therapy Evaluation Program since 2014.
She has published more than 70 peer-reviewed articles and served as an editorial board member for multiple scientific journals including Human Pathology.
- Medical School
- Beijing Medical University (1986)
- Beijing University Hospital (1989), Pediatrics
- Graduate School
- Beijing Medical University (1991)
- Mayo Clinic (1995), Physiology
- UT Southwestern Medical Center (1999), Molecular Nephrology Research
- University of Pittsburgh Medical Center (2003), Anatomic & Clinical Pathology
- University of Pittsburgh Medical Center Magee Womens Hospital (2004), Breast & Gynecologic Pathology
- Harvard Medical School/Beth Israel Deaconess Medical Center (2005), Cytopathology
- Breast Cancer and Gynecologic Cancer Pathology
- Diagnostic, prognostic and predictive tumor biomarkers
- Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin.
- Yang C, Sun L, Zhang L, Zhou L, Zhao M, Peng Y, Niu D, Li Z, Huang X, Kang Q, Jia L, Lai J, Cao D Am. J. Surg. Pathol. 2017 Sep
- Nuclear receptor NR4A1 is a tumor suppressor down-regulated in triple-negative breast cancer.
- Wu H, Bi J, Peng Y, Huo L, Yu X, Yang Z, Zhou Y, Qin L, Xu Y, Liao L, Xie Y, Conneely OM, Jonkers J, Xu J Oncotarget 2017 Aug 8 33 54364-54377
- KIT Mutations and CD117 Overexpression Are Markers of Better Progression-Free Survival in Vulvar Melanomas.
- Dias-Santagata D, Selim MA, Su Y, Peng Y, Vollmer R, Chlopik A, Marti GT, Paral K, Shalin S, Shea CR, Puig S, Fernandez-Figueras MT, Biernat W, Rys J, Marszalek A, Hoang MP Br. J. Dermatol. 2017 Jul
- Update on Immunohistochemical Analysis in Breast Lesions.
- Peng Y, Butt YM, Chen B, Zhang X, Tang P Arch. Pathol. Lab. Med. 2017 Jun
- Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
- Krishnan SR, Nair BC, Sareddy GR, Roy SS, Natarajan M, Suzuki T, Peng Y, Raj G, Vadlamudi RK Breast Cancer Res. Treat. 2015 Mar
- Quantification of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Using the Ventana Image Analysis System: Correlation With Gene Amplification by Fluorescence In Situ Hybridization: The Importance of Instrument Validation for Achieving High (>95%) Concordance Rate.
- Dennis J, Parsa R, Chau D, Koduru P, Peng Y, Fang Y, Sarode VR Am. J. Surg. Pathol. 2015 Jan
- Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma (TNBC): comparison with GATA3 expression and PELP1's potential role in TNBC
- Dang D, Raj G, Sarode V, Molberg K, Vadlamudi R and Peng Y* humpath. 2015 46 12 1829-1835
- KIF14 Promotes AKT Phosphorylation and Contributes to Chemoresistance in Triple-Negative Breast Cancer.
- Singel SM, Cornelius C, Zaganjor E, Batten K, Sarode VR, Buckley DL, Peng Y, John GB, Li HC, Sadeghi N, Wright WE, Lum L, Corson TW, Shay JW Neoplasia 2014 Mar 16 3 247-256.e2
- Cutaneous and mammary apocrine carcinomas have different immunoprofiles.
- Piris A, Peng Y, Boussahmain C, Essary LR, Gudewicz TM, Hoang MP Hum. Pathol. 2014 Feb 45 2 320-6
- Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer.
- Cockburn A, Yan J, Rahardja D, Euhus D, Peng Y, Fang Y, Rumnong Sarode V Hum. Pathol. 2014 Feb 45 2 249-58
Invasive Breast Carcinomas. In Peng Y, Kong C, and Chen Y. Practical Breast Pathology. Atkins K and Kong C (eds.), a volume in the Pattern Recognition Series. Kevin O. Leslie and Mark R.Wick (eds.).
Peng Y, Kong C, and Chen Y. (2013; 147-212). Philadelphia, PA, Elsevier
Honors & Awards
- Chair, Pathology Faculty Mentoring Committee
- Member, Abstract Review Board of United States and Canadian Academy of Pathology (Breast Pathology Category)
- Member, UT Southwestern Medical School Deans Standing Committee (Faculty Council and LCME)
- President, International Association of Chinese Pathologists (IACP)
- President, UT Southwestern Faculty Senate
- President-Elect, North Texas Society of Pathologists (NTSP)
- Distinguished Young Investigator Award in Medicine
Beijing, China (1993)
- Distinguished Scientist Award of Canada China Child Health Foundation
- Best National Medical Article Award